TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23232158

Group type: EXPERIMENTAL
Intervention: Combination therapy (virtual reality + modified constraint-induced movement therapy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy in a virtual environment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 19944596

Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 16
Study: 17437361

Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg IV initial dose then 50 mg IV every 12 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem-cilastatin (500 mg IV every 6 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study: 16340523

Group type: EXPERIMENTAL
Intervention: Scleral buckle (SB) surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 150
Study: 12022008

Group type: EXPERIMENTAL
Intervention: Retinoscopy performed immediately after the orthoptic examination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Retinoscopy performed during an additional visit
Number of subjects: 32
Study: 9640144

Group type: EXPERIMENTAL
Intervention: Ventilatory assistance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation and two levels of pressure assistance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Different waveforms of flow or pressure from the ventilators
Number of subjects: 12
Study: 8043290

Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (Group II)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia (Group I)
Number of subjects: 281
Study: 3177528

Group type: EXPERIMENTAL
Intervention: Nylon brush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotton‐tipped swab and wooden spatula
Number of subjects: 0
Study: 29624630

Group type: EXPERIMENTAL
Intervention: Active group (tooth whitening with photoactivated gel)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 28114928

Group type: EXPERIMENTAL
Intervention: Scaling and root planing + photodynamic therapy (PDT) + oral hygiene orientation (OHO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Oral hygiene orientation (OHO) + supragingival treatment + simulation of using photodynamic therapy (PDT)
Number of subjects: 64
Study: 25092036

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 23245469

Group type: EXPERIMENTAL
Intervention: MoodGYM program (high adherence)
Number of subjects: 1477

Group type: EXPERIMENTAL
Intervention: MoodGYM program (low adherence)
Number of subjects: 1477

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 1477
Study: 21985296

Group type: EXPERIMENTAL
Intervention: Implementation of core elements of the Chronic Care Model via a specially trained Chronic Care Coach
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 352
Study: 17673699

Group type: EXPERIMENTAL
Intervention: Custom-made device
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thermoplastic device
Number of subjects: 35
Study: 17070446

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Basal Insulin
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Basal and Prandial Insulin
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Overall (Grades 2-4)
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Overall (Grades 3-4)
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Younger patients (<45 years)
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Older patients (>=45 years)
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Normal weight (BMI <25 kg/m2)
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Overweight (BMI >=25 kg/m2)
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: HbA1c <7%
Number of subjects: 5063

Group type: COMPARATOR
Intervention: HbA1c >=7%
Number of subjects: 5063

Group type: EXPERIMENTAL
Intervention: Islet autoantibody-positive patients
Number of subjects: 5063

Group type: COMPARATOR
Intervention: Islet autoantibody-negative patients
Number of subjects: 5063
Study: 14624050

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs)
Number of subjects: 300

Group type: COMPARATOR
Intervention: corn oil
Number of subjects: 300
Study: 11115311

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study: 9200390

Group type: EXPERIMENTAL
Intervention: Accelerated tissue plasminogen activator (TPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase with subcutaneously administered heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase with intravenously administered heparin
Number of subjects: 0
Study: 1410141

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg daily for 8 weeks, followed by 4 weeks of continuation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (2 weeks followed by 4 weeks of continuation)
Number of subjects: 40
Study: 3933455

Group type: EXPERIMENTAL
Intervention: Amino acid solution containing 15.6% branched-chain amino acids
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amino acid solutions with 50% branched-chain amino acids
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amino acid solutions with 100% branched-chain amino acids
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard amino acid formula
Number of subjects: 15
Study: 30862454

Group type: EXPERIMENTAL
Intervention: French version of the QUIP-RS
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: QUIP-RS total score
Number of subjects: 280
Study: 30829275

Group type: EXPERIMENTAL
Intervention: Games and story therapy along with motivational intervention (Group B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Reading and writing therapy along with motivational intervention (Group C)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Motivational intervention alone (Group A)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 82
Study: 26786576

Group type: COMPARATOR
Intervention: PLBO/WHEY
Number of subjects: 22

Group type: COMPARATOR
Intervention: VILD/CTRL
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: VILD/WHEY
Number of subjects: 22
Study: 24770617

Group type: EXPERIMENTAL
Intervention: IVIG+rituximab
Number of subjects: 15

Group type: COMPARATOR
Intervention: IVIG+placebo
Number of subjects: 15
Study: 22472994

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 30 mg twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 100 mg twice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control phase (no gemfibrozil)
Number of subjects: 10
Study: 19810670

Group type: EXPERIMENTAL
Intervention: Learner‐centered simulation intervention with trained actors as standardized family members, including a formal training session and a 60-minute practice session
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with current standard education only
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100
Study: 17956562

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 20
Study: 16195165

Group type: EXPERIMENTAL
Intervention: Progressive strength training (FMT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (FMC)
Number of subjects: 26
Study: 11897925

Group type: EXPERIMENTAL
Intervention: 40 mg telmisartan + 12.5 mg HCTZ
Number of subjects: 327

Group type: COMPARATOR
Intervention: 40 mg telmisartan
Number of subjects: 327
Study: 10360855

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (10% arginine hydrochloride, 30 g over 15 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 8588693

Group type: EXPERIMENTAL
Intervention: Nitroprusside (1.2 and 3.6 mg per nasal cavity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroprusside (7.2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1790038

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (21% of total calories from fat)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Normal diet (38% of total calories from fat)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 253

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 253
Study: 7148839

Group type: EXPERIMENTAL
Intervention: Theophylline pharmacokinetic monitoring service
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care without pharmacokinetic monitoring)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (with steady-state concentrations drawn)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (without steady-state concentrations drawn)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study: 30408199

Group type: COMPARATOR
Intervention: CVD screening plus incentive double points (Group 3)
Number of subjects: 570

Group type: COMPARATOR
Intervention: CVD screening with routine points (Group 2)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Routine points (Group 1, control)
Number of subjects: 570
Study: 28829938

Group type: COMPARATOR
Intervention: Ketac Cem EasyMix (GIC, positive control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SeT
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Maxcem Elite (Max)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Smart Cem2 (Smart)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: RelyX Unicem 2 (Unicem2)
Number of subjects: 70
Study: 25401456

Group type: EXPERIMENTAL
Intervention: Dynamic response ankle-foot orthoses (DR-AFO)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 3
Study: 22520276

Group type: EXPERIMENTAL
Intervention: Recovery Management Intervention (RMI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 100
Study: 21145848

Group type: EXPERIMENTAL
Intervention: Danoprevir 200 mg q8 h
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Danoprevir 200 mg q12 h
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Danoprevir 300 mg q12 h (non-responders)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 19441869

Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg every 12 hours for 7-14 days
Number of subjects: 802

Group type: COMPARATOR
Intervention: Standard therapy (vancomycin 1 g every 12 hours with or without aztreonam 1 g every 8 hours)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg every 12 hours for 5-14 days
Number of subjects: 802

Group type: COMPARATOR
Intervention: Vancomycin 1 g plus aztreonam 1 g every 12 hours
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 802
Study: 16774462

Group type: EXPERIMENTAL
Intervention: All4You! intervention
Number of subjects: 988
Study: 15612861

Group type: EXPERIMENTAL
Intervention: Collaborative Problem Solving (CPS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Parent Training (PT)
Number of subjects: 47
Study: 11747151

Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated sheath (HCS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonhydrophilic sheath (NHS)
Number of subjects: 90
Study: 9360143

Group type: EXPERIMENTAL
Intervention: Silicone coated oxygenator (Mera Excelung Binding Prim HPO 15 H‐C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Binding Prim HPO 25 H‐C (heparin coated oxygenator)
Number of subjects: 16
Study: 7685588

Group type: EXPERIMENTAL
Intervention: Aprotinin (25,000 U/kg after induction of anesthesia, 25,000 U/kg added to the prime, 25,000 U/kg every hour of cardiopulmonary bypass)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (children without aprotinin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 48
Study: 3573540

Group type: COMPARATOR
Intervention: 4.0 mEq/liter Ca dialysate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intraperitoneal 1,25(OH)2D3
Number of subjects: 11
Study: 28759534

Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 110% Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 115% Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 120% Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 125% Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 130% Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supramaximal incline treadmill training at 140% Vmax
Number of subjects: 12
Study: 28063075

Group type: EXPERIMENTAL
Intervention: Problem‐Solving Therapy for adherence and depression (PST‐AD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Enhanced Usual Care (Control)
Number of subjects: 32
Study: 27501119

Group type: EXPERIMENTAL
Intervention: 1 W/kg (low RF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 W/kg (high RF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 W/kg (sham)
Number of subjects: 36
Study: 24421289

Group type: EXPERIMENTAL
Intervention: Alcohol infusion (target BrAC = 0.06 g/dl)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 295
Study: 23220322

Group type: EXPERIMENTAL
Intervention: Fuji II LC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fuji Filling LC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cavity Conditioner (20% polyacrylic acid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self Conditioner (no-rinse conditioner)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No conditioner
Number of subjects: 0
Study: 21194607

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 0.5 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 2.0 g
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium 1.0 g BID for 7 days (multiple doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefotetan disodium (all doses)
Number of subjects: 30
Study: 16483699

Group type: EXPERIMENTAL
Intervention: Medicated dressing with Rifocort (camphorated parachlorophenol and iodoform)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (merely sutured)
Number of subjects: 40
Study: 16231622

Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 20
Study: 12113323

Group type: EXPERIMENTAL
Intervention: Human synthetic secretin, mean dose 3.4 clinical units, administered intravenously every 4th week, on three occasions.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo, administered intravenously every 4th week, on three occasions.
Number of subjects: 6
Study: 10446103

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin concentrations in patients taking NSAIDs
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Faecal calprotectin concentrations
Number of subjects: 312

Group type: COMPARATOR
Intervention: Four day faecal excretion of (111)In labelled white cells
Number of subjects: 312
Study: 7788039

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg daily (divided into two doses) for 12 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 105
Study: 1977479

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ipsapirone (IPS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 357233

Group type: EXPERIMENTAL
Intervention: Indoprofen (300 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen (250 mg)
Number of subjects: 40
Study: 30972808

Group type: EXPERIMENTAL
Intervention: Social and emotional learning intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 28910165

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 106
Study: 25700100

Group type: EXPERIMENTAL
Intervention: Caffeine (6mg.kg(‐1) body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (artificial sweetener)
Number of subjects: 10
Study: 24280464

Group type: EXPERIMENTAL
Intervention: Benson's relaxation technique (audiotape listened to twice a day for 20 minutes for 8 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 86
Study: 21682597

Group type: EXPERIMENTAL
Intervention: Emergency ureteroscopy (Group A)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Delayed ureteroscopy (Group B)
Number of subjects: 271
Study: 19335924

Group type: EXPERIMENTAL
Intervention: Daidzein (DAI) and daidzein-7-O-beta-D-glucoside (DG) (1 mg DAI aglycone equivalents/kg body weight)
Number of subjects: 5
Study: 16118096

Group type: EXPERIMENTAL
Intervention: SANS alone (Group 1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SANS combined with low-dose anticholinergic (5 mg oxybutynin hydrochloride) (Group 2)
Number of subjects: 43
Study: 12097666

Group type: EXPERIMENTAL
Intervention: Soy milk (500 mL twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 40
Study: 10401776

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (adjustable to 100 or 25 mg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 8523357

Group type: EXPERIMENTAL
Intervention: Active device (pulsed electrical stimulation)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 78
Study: 2108908

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7208538

Group type: EXPERIMENTAL
Intervention: Hydrophilic mucilage with an 800 calorie hypoglucidic diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 22
Study: 31017851

Group type: EXPERIMENTAL
Intervention: Individual treatment for target morpheme
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group treatment for target morpheme
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control morpheme
Number of subjects: 20
Study: 28903777

Group type: EXPERIMENTAL
Intervention: NF54-CPS immunization
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (uninfected mosquitoes)
Number of subjects: 39
Study: 25406730

Group type: EXPERIMENTAL
Intervention: Albiglutide (30 mg/week)
Number of subjects: 685

Group type: COMPARATOR
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 685
Study: 22982585

Group type: EXPERIMENTAL
Intervention: Preterm subjects (PT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 19
Study: 21499201

Group type: EXPERIMENTAL
Intervention: Increased tidal volume (IV(T)) achieved by increasing inspired plateau pressure 0.04 cmH₂O kg⁻¹ above initial plateau pressure.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal tidal volume (NV(T)) with unchanged end‐tidal carbon dioxide partial pressure (P(ET)CO₂).
Number of subjects: 20
Study: 19704068

Group type: EXPERIMENTAL
Intervention: COPP/ABVD (arm A)
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: BEACOPP baseline (arm B)
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: BEACOPP escalated (arm C)
Number of subjects: 1196
Study: 16838651

Group type: EXPERIMENTAL
Intervention: High dose IFNalpha therapy (HDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose IFNalpha therapy (LDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFNbeta in combination with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFNbeta gene therapy
Number of subjects: 0
Study: 15661439

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11872106

Group type: EXPERIMENTAL
Intervention: Myofascial trigger-point massage therapy
Number of subjects: 30
Study: 10094253

Group type: EXPERIMENTAL
Intervention: Continued therapy with barbiturates, phenytoin, and valproate
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Withdrawal of carbamazepine
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Withdrawal of phenobarbitone
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Standard antiepileptic drugs as monotherapy
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 1013
Study: 9345394

Group type: EXPERIMENTAL
Intervention: Rebif (recombinant human interferon beta) administered subcutaneously at a dose of 8 million international units (MIU) once a week for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2179779

Group type: EXPERIMENTAL
Intervention: Relaxation response
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reading group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Charting group
Number of subjects: 46
Study: 7430545

Group type: EXPERIMENTAL
Intervention: Indomethacin collyrium administered prior to surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no indomethacin)
Number of subjects: 20
Study: 31550863

Group type: EXPERIMENTAL
Intervention: Capecitabine combined with omeprazole
Number of subjects: 72

Group type: COMPARATOR
Intervention: Capecitabine alone (Control)
Number of subjects: 72
Study: 28007620

Group type: EXPERIMENTAL
Intervention: O2 group (received oxygen at 3 L/min via nasal prongs for three postoperative nights)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: O2 group
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no oxygen)
Number of subjects: 123